{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:30:35Z","timestamp":1777923035419,"version":"3.51.4"},"reference-count":41,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"\n Background:<\/jats:title>\n \n Prevalence of extended-spectrum beta-lactamase-producing\n Escherichia coli<\/jats:italic>\n (ESBL-\n E. coli<\/jats:italic>\n ) is increasing worldwide, but greatly varies geographically. We compared the prevalence of ESBL-\n E. coli<\/jats:italic>\n infections at four distinct health care facilities in San Francisco, California.\n <\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n Antimicrobial susceptibility reports were obtained for\n E. coli<\/jats:italic>\n isolates from (1) a county hospital, (2) a public skilled nursing facility, (3) a university hospital, and (4) a Veterans Affairs (VA) Medical Center. We compared change in frequency of ESBL-\n E. coli<\/jats:italic>\n and antimicrobial resistance to trimethoprim-sulfamethoxazole between 2012 and 2018.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n From 2012 to 2018, frequency of ESBL-\n E. coli<\/jats:italic>\n increased in urine and nonurine isolates from the county hospital (urine: 1.1% per year, 95% confidence interval [CI]: 0.5\u20131.6,\n p<\/jats:italic>\n \u2009<\u20090.01; nonurine: 1.9% per year, 95% CI: 0.9\u20132.9,\n p<\/jats:italic>\n \u2009<\u20090.01) and in urine isolates from the VA hospital (0.9% per year, 95% CI: 0.3\u20131.4,\n p<\/jats:italic>\n \u2009<\u20090.01). The frequency of trimethoprim-sulfamethoxazole resistance fluctuated in all facilities.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n \n At the skilled nursing facility, the prevalence of ESBL-\n E. coli<\/jats:italic>\n was highest, but remained stable over time, while the prevalence of ESBL-\n E. coli<\/jats:italic>\n increased among urine and nonurine isolates at the county hospital and urine isolates at the VA hospital. The temporal trend of ESBL-\n E. coli<\/jats:italic>\n infections, even within one city, varied by health care facility.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1089\/mdr.2020.0058","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T13:39:27Z","timestamp":1593178767000},"page":"154-161","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Differential Trends in Extended-Spectrum Beta-Lactamase-Producing\n Escherichia coli<\/i>\n Infections in Four Health Care Facilities in a Single Metropolitan Area: A Retrospective Analysis"],"prefix":"10.1177","volume":"27","author":[{"given":"Eva","family":"Raphael","sequence":"first","affiliation":[{"name":"Department of Family and Community Medicine and University of California, San Francisco, San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry F.","family":"Chambers","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_3_5_3_2","first-page":"Jordan","article-title":"Extended-spectrum beta-lactamase producing E","author":"Al-Jamei S.A.","year":"2019","unstructured":"Al-Jamei S.A., , Albsoul A.Y, , Bakri F.G, , and Al-Bakri A.G.. 2019. Extended-spectrum beta-lactamase producing E. coli in urinary tract infections: a two-center, cross-sectional study of prevalence, genotypes and risk factors in, Amman, Jordan. J. Infect. Public Health 12:21\u201325.","journal-title":"coli in urinary tract infections: a two-center, cross-sectional study of prevalence, genotypes and risk factors in"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.02.012"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198621"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1556\/030.64.2017.030"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.4103\/JLP.JLP_149_16"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.02.2264"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30605-4"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taw102"},{"key":"e_1_3_5_11_2","unstructured":"Centers for Disease Control and Prevention (CDC). 2019. Antibiotic Resistance Threats in the United States 2019. U.S. Department of Health and Human Services CDC Atlanta GA."},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S203572"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2018.254"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm318"},{"key":"e_1_3_5_15_2","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2016. Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100S. 26th ed. CLSI Wayne PA."},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/2047-2994-3-9"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03655-3"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70041-0"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.03.004"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2017.49.3.184"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph6111335"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis942"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2209.160148"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-018-0326-0"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz119"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3804-y"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2018.05.006"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy357"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2017.156"},{"key":"e_1_3_5_30_2","first-page":"1184","article-title":"Impact of long-term care facility residence on the antibiotic resistance of urinary tract Escherichia coli and Klebsiella","volume":"72","author":"Rosello A.","year":"2017","unstructured":"Rosello A., , Hayward A.C, , Hopkins S., , Horner C., , Ironmonger D., , Hawkey P.M, , and Deeny S.R.. 2017. Impact of long-term care facility residence on the antibiotic resistance of urinary tract Escherichia coli and Klebsiella. J. Antimicrob. Chemother. 72:1184\u20131192.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1086\/317489"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214327"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.59"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.11.2193"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/664055"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.215"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0880-5"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.6.517"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2015.11.013"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025239"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198809153191114"},{"key":"e_1_3_5_42_2","unstructured":"Centers for Disease Control and Prevention (CDC). 2019. Core Elements of Hospital Antibiotic Stewardship Programs. U.S. Department of Health and Human Services CDC Atlanta GA."}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2020.0058","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2020.0058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2020.0058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:37:33Z","timestamp":1777667853000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2020.0058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"alternative-id":["10.1089\/mdr.2020.0058"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2020.0058","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]}}}